0001127602-23-023040.txt : 20230821 0001127602-23-023040.hdr.sgml : 20230821 20230821193630 ACCESSION NUMBER: 0001127602-23-023040 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230814 FILED AS OF DATE: 20230821 DATE AS OF CHANGE: 20230821 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Busch Matthew C. CENTRAL INDEX KEY: 0001987926 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 231190664 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 3 1 form3.xml PRIMARY DOCUMENT X0206 3 2023-08-14 0 0000318154 AMGEN INC AMGN 0001987926 Busch Matthew C. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 1 VP, Finance & CAO Common Stock 4596 D Nqso (Right to Buy) 177.46 2020-04-27 2028-04-27 Common Stock 1257 D Nqso (Right to Buy) 177.31 2021-05-03 2029-05-03 Common Stock 1476 D Nqso (Right to Buy) 236.36 2022-05-05 2030-05-05 Common Stock 1558 D Nqso (Right to Buy) 239.64 2023-04-30 2031-04-30 Common Stock 1086 D Nqso (Right to Buy) 230.92 2024-05-02 2032-05-02 Common Stock 1753 D Nqso (Right to Buy) 235.97 2025-05-02 2033-05-02 Common Stock 2508 D These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 64 RSUs which will vest on 5/5/2024; 84 RSUs which will vest in installments of 41 on 4/30/2024 and 43 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; 1,496 RSUs which will vest in installments of 493 on 11/5/2023, 494 on 11/5/2024 and 509 on 11/5/2025; 214 RSUs which will vest in installments of 70 on 5/2/2024, 71 on 5/2/2025, and 73 on 5/2/2026; and 296 RSUs which will vest in installments of 97 on 5/2/2025, 98 on 5/2/2026 and 101 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 126 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. 1,257 of these non-qualified stock options have vested and are exercisable. 1,476 of these non-qualified stock options have vested and are exercisable. 1,028 of these non-qualified stock options have vested and 530 will vest and become exercisable on 5/5/2024. 358 of these non-qualified stock options have vested and the remaining options will vest and become exercisable in installments of 358 on 4/30/2024 and 370 on 4/30/2025. These non-qualified stock options will vest and become exercisable in two installments of 578 on 5/2/2024 and 5/2/2025 and one installment of 597 on 5/2/2026. These non-qualified stock options will vest and become exercisable in installments of 827 on 5/2/2025, 828 on 5/2/2026 and 853 on 5/2/2027. /s/ Matthew C. Busch 2023-08-21 EX-24 2 doc1.txt POWER OF ATTORNEY (PUBLIC): POA Exhibit 24 Power of Attorney Know all men by these presents, that the undersigned hereby constitutes and appoints each of Dennis Yai and Andrea A. Robinson, signing singly, the undersigned's true and lawful attorney-in-fact to execute for and on behalf of the undersigned Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, as may be required as a result of the undersigneds position as an officer and/or director of Amgen Inc. (the "Company"). The undersigned hereby grants to each such attorney-in-fact full power and authority to execute such Forms 3, 4 and 5 as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigneds holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys- in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of July, 2023. /s/ Matthew C. Busch Name: Matthew C. Busch